Hepatitis D Virus: Introduction and Epidemiology - PubMed (original) (raw)

Review

Hepatitis D Virus: Introduction and Epidemiology

Mario Rizzetto. Cold Spring Harb Perspect Med. 2015.

Abstract

Hepatitis D is caused by the hepatitis D virus (HDV), a unique RNA pathogen that requires the hepatitis B surface antigen (HBsAg) to infect. Hepatitis D is transmitted by the parenteral route. The main susceptible group is patients with chronic HBsAg infection who become superinfected with the virus. Hepatitis D occurs throughout the globe, but control of hepatitis B virus (HBV) in the last two decades has consistently diminished the circulation of HDV in industrialized countries. However, hepatitis D remains a medical issue for injecting drug users (IDUs), as well as immigrants from endemic HDV areas, who are reintroducing the infection in Europe.

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

PubMed Disclaimer

Figures

Figure 1.

Virologic and serologic markers in coinfection (hepatitis D virus [HDV]/hepatitis B virus [HBV]) and superinfection (hepatitis B surface antigen [HBsAg]/HDV).

Figure 2.

Schematic representation of the main areas of HDV globally onto which the predominant hepatitis D virus (HDV) genotype for each geographical area has been superimposed. (From Negro 2014; reproduced from © 2013 John Wiley and Sons.)

Figure 3.

Changes in the prevalence of anti-HD in HBsAg-carriers with liver disease in Italy; 2009 are incident cases.

Figure 4.

Epidemiology of hepatitis D virus (HDV) in Europe in 2012. Prevalence of immigrants among HDV+. (1) Data from Buti et al. (2011), (2) data from Cross et al. 2008, (3) data from Wedemeyer and Manns 2010, (4) data from Rizzetto and Ciancio 2012, and (5) data from Brancaccio et al. 2014.

Similar articles

• Epidemiology of hepatitis D.
  Rizzetto M, Ciancio A. Rizzetto M, et al. Semin Liver Dis. 2012 Aug;32(3):211-9. doi: 10.1055/s-0032-1323626. Epub 2012 Aug 29. Semin Liver Dis. 2012. PMID: 22932969 Review.
• The adventure of delta.
  Rizzetto M. Rizzetto M. Liver Int. 2016 Jan;36 Suppl 1:135-40. doi: 10.1111/liv.13018. Liver Int. 2016. PMID: 26725911 Review.
• The medical impact of hepatitis D virus infection in Uzbekistan.
  Khodjaeva M, Ibadullaeva N, Khikmatullaeva A, Joldasova E, Ismoilov U, Colombo M, Caviglia GP, Rizzetto M, Musabaev E. Khodjaeva M, et al. Liver Int. 2019 Nov;39(11):2077-2081. doi: 10.1111/liv.14243. Epub 2019 Sep 20. Liver Int. 2019. PMID: 31505080
• Hepatitis D (DELTA).
  Rizzetto M. Rizzetto M. New Microbiol. 2022 Jul;45(3):149-154. New Microbiol. 2022. PMID: 35920869
• Hepatitis delta in HIV-infected individuals in Europe.
  Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Soriano V, et al. AIDS. 2011 Oct 23;25(16):1987-92. doi: 10.1097/QAD.0b013e32834babb3. AIDS. 2011. PMID: 21857493

Cited by

• Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
  Goyal A, Romero-Severson EO. Goyal A, et al. PLoS One. 2018 Sep 7;13(9):e0203831. doi: 10.1371/journal.pone.0203831. eCollection 2018. PLoS One. 2018. PMID: 30192887 Free PMC article.
• Hepatitis D-associated hospitalizations in the United States: 2010-2018.
  Wasuwanich P, Striley CW, Kamili S, Teshale EH, Seaberg EC, Karnsakul W. Wasuwanich P, et al. J Viral Hepat. 2022 Mar;29(3):218-226. doi: 10.1111/jvh.13645. Epub 2022 Feb 2. J Viral Hepat. 2022. PMID: 35075719 Free PMC article.
• A potent human neutralizing antibody Fc-dependently reduces established HBV infections.
  Li D, He W, Liu X, Zheng S, Qi Y, Li H, Mao F, Liu J, Sun Y, Pan L, Du K, Ye K, Li W, Sui J. Li D, et al. Elife. 2017 Sep 26;6:e26738. doi: 10.7554/eLife.26738. Elife. 2017. PMID: 28949917 Free PMC article.
• Viral hepatitis vaccination during pregnancy.
  Zhao Y, Jin H, Zhang X, Wang B, Liu P. Zhao Y, et al. Hum Vaccin Immunother. 2016 Apr 2;12(4):894-902. doi: 10.1080/21645515.2015.1132129. Hum Vaccin Immunother. 2016. PMID: 26833263 Free PMC article. Review.
• Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma.
  Xu L, Xu Y, Zhang F, Xu P, Wang L. Xu L, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Jan 19;53(1):64-72. doi: 10.3724/zdxbyxb-2023-0481. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 38426692 Free PMC article. Review. Chinese, English.

References

1. 1. Abbas Z, Jafri W, Raza S. 2010. Hepatitis D: Scenario in the Asia-Pacific region. World J Gastroenterol 16: 554–562. - PMC - PubMed
2. 1. Amini N, Alavian SM, Kabir A, Aalaei-Andabili SH, Saiedi Hosseini SY, Rizzetto M. 2013. Prevalence of hepatitis D in the eastern Mediterranean region: Systematic review and meta analysis. Hepat Mon 13: e8210. - PMC - PubMed
3. 1. Arakawa Y, Moriyama M, Taira M, Hayashi N, Tanaka N, Okubo H, Sugitani M. 2000. Molecular analysis of hepatitis D virus infection in Miyako Island, a small Japanese island. J Viral Hepat 7: 375–381. - PubMed
4. 1. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M. 2011. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: Still a serious problem to consider. J Viral Hepat 18: 518–524. - PubMed
5. 1. Baig S, Siddiqui AA, Ahmed WU, Qureshi H, Arif A. 2009. Frequency of hepatitis C and D super infection in patients with hepatitis B related complex liver disorders. J Coll Physicians Surg Pak 19: 699–703. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations